Forefront of developing new possibilities
through innovative technology
Platform Technology
Viral vector platform
Enhanced transduction efficacy
We are developing technology to increase the expression of AAV cassettes in cells and tissues by utilizing elements that improve the efficiency of transduction.
Cell/Tissue specific targeting
We are developing technology that will enable AAV cassettes and capsids to express selectively in specific cells and tissues.
Tissue de-targeting
ENCell is developing "de-targeting" technology to reduce tropism and minimize liver specificity while maintaining or enhancing tropism for other tissues. This will be achieved using the company's capsid modification technology.
Immune evasion
ENCell is developing technology that modifies capsids to reduce immune responses and reactions to antibodies.
Viral Vector Manufacturing Process
Seed expansion
Virus
production
Harvest /
Clarify
Capture
Polishing
Formulation
Filling
Facilitating the transfer for developed processes to GMP
- Characterization
- Adherent/non-adherent cells
Cell bank characterization analysis
Scale-up research
Key parameter-based
process optimization
- Characterization
- Raw material
drug regulatory testing + Stability testing
Production (Vial/Bag)
Quality control during
the filling process.
- Characterization
- Raw material
drug regulatory testing + Stability testing